According to Celsus Therapeutics, it has received patents for several of its pipeline drugs, including MRX-4, and intranasal multifunctional anti-inflammatory drug for the treatment of allergic rhinitis. Celsus changed its name from Morria Biopharmaceuticals in March 2013.
Celsus CEO Gur Roshwalb said, “We are pleased that the USPTO has issued the necessary patents protecting the intellectual property surrounding our clinical and pre-clinical drug candidates MRX-4, MRX-5, MRX-6, and OPT-1. We are working every day to bring patients our first-in-class, multifunctional anti-inflammatory drugs for multiple, specific indications. Since November 2012, we have added an additional 4 US patents, strengthening our already outstanding intellectual property portfolio. ”
According to the company, a Phase 2 trial of MRX-4 showed that patients using the intranasal formulation efficacy experienced greater reduction in allergic rhinitis symptoms than did patients using a placebo.
Celsus is also developing an inhaled drug, CFX-1, for the treatment of cystic fibrosis.
Read the Celsus press release.
